Serum microRNA-193b as a promising biomarker for prediction of chemoradiation sensitivity in esophageal squamous cell carcinoma patients.

摘要: Esophageal squamous cell carcinoma (ESCC) is the most predominantly occurring type of esophageal cancer worldwide. Locally advanced ESCC patients are treated by neoadjuvant chemoradiation for tumor downstaging prior to resection. Patients receiving this treatment have an increased expectation cure via following resection and better survival outcomes. However, not all respond well poor responders suffer from treatment-associated toxicity complications without benefits. No method currently available predict patient response exclude ineffective treatment. To address clinical limitation, present study aimed identify non-invasive biomarkers predicting response. Due features microRNA (miRNA) in diagnosis, prognosis prediction, serum miRNA arrays were performed potential miRNA(s) that may be used prediction ESCC. Using array compare pre-treatment sample pools 10 good responders, identified miR-193b, miR-942 miR-629* as candidate miRNAs Subsequent validation using reverse transcription-quantitative polymerase chain reaction confirmed however miR-629*, significantly sera 24 compared with 23 responders. Further analyses receiver operating characteristic curve revealed a strong predictive power miR-193b on discriminating chemoradiation. In addition, high level was associated Therefore, considered promising biomarker post-therapy patients.